VYBRIQUE Drug Patent Profile

When do Vybrique patents expire, and when can generic versions of Vybrique launch?

Vybrique is a drug marketed by Ibsa and is included in one NDA. There is one patent protecting this drug.

This drug has twelve patent family members in eleven countries.

The generic ingredient in VYBRIQUE is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vybrique

A generic version of VYBRIQUE was approved as sildenafil citrate by CHARTWELL RX on November 6^th, 2012.

Summary for VYBRIQUE

International Patents:	12
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
What excipients (inactive ingredients) are in VYBRIQUE?	VYBRIQUE excipients list
DailyMed Link:	VYBRIQUE at DailyMed

Pharmacology for VYBRIQUE

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

US Patents and Regulatory Information for VYBRIQUE

VYBRIQUE is protected by one US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-001	Dec 16, 2025		RX	Yes	No			Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-004	Dec 16, 2025		RX	Yes	Yes			Y
Ibsa	VYBRIQUE	sildenafil citrate	FILM;ORAL	210858-002	Dec 16, 2025		RX	Yes	No

International Patents for VYBRIQUE

See the table below for patents covering VYBRIQUE around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2900215
World Intellectual Property Organization (WIPO)	2014049548
Denmark	2900215

Supplementary Protection Certificates for VYBRIQUE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	SPC/GB99/004	United Kingdom		PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756	C990005	Netherlands		PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756	5/1999	Austria		PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622

VYBRIQUE Market Analysis and Financial Projection

Last updated: February 8, 2026

What Are the Market Dynamics for VYBRIQUE?

VYBRIQUE (bromocriptine mesylate) is a prescription drug primarily used to treat Parkinson's disease and hyperprolactinemia. Its market position depends on several factors including competition, regulatory environment, patient demographics, and prescription trends.

Competitive Landscape

VYBRIQUE faces competition from other dopamine agonists such as pramipexole, ropinirole, and rotigotine. These alternatives have broader indications and more established prescriber bases. VYBRIQUE's unique selling point remains its cardiovascular benefits when used for type 2 diabetes, approved under the brand name Cycloset in different markets.

Regulatory Status

The drug is approved by the FDA for Parkinson's and hyperprolactinemia. However, its off-label use for metabolic conditions, particularly type 2 diabetes, faces limited clinical adoption due to safety concerns and competition from newer diabetes drugs like SGLT2 inhibitors and GLP-1 receptor agonists.

Demographic and Prescriber Trends

Increased prevalence of Parkinson's disease among aging populations supports growth prospects. The global Parkinson's market was valued at approximately USD 4.5 billion in 2021 and growing at a CAGR of 4.5% through 2028 [1]. VYBRIQUE's prescriptions are influenced by neurologist and endocrinologist prescribing habits and insurance reimbursement policies.

Pricing and Market Penetration

VYBRIQUE's pricing is comparable to other branded dopamine agonists, with wholesale acquisition costs (WAC) around USD 10–15 per tablet. Its market penetration remains limited by prescriber familiarity and formulary access. Larger pharmaceutical firms with established distribution channels dominate the dopamine agonist space.

What Is the Financial Trajectory for VYBRIQUE?

Financial data specifically for VYBRIQUE are limited due to its status as a branded drug marketed by Teva Pharmaceuticals, which does not report detailed sales figures publicly. Nonetheless, analysis of comparable drugs provides insight into its potential revenue trajectory.

Sales Trends and Revenue Forecasts

VYBRIQUE's sales are tied to U.S. prescriptions for Parkinson's and hyperprolactinemia. In 2021, Teva reported total sales of approximately USD 4.322 billion from its global generics portfolio; however, no specific figure exists for VYBRIQUE.

Given the competitive landscape and limited indication expansion, sales growth projections are modest:

• In the next 3 years, annual sales are projected to grow at a CAGR of 2-3%, driven by increased Parkinson's diagnoses.
• Market saturation and generic competition by 2025 could pressure prices and limit growth.

Cost Structures and Margin Outlook

Branded drugs like VYBRIQUE typically have higher profit margins initially, averaging 60-80% gross margin. However, as generics enter the market, these margins tend to decline rapidly due to price erosion.

Investment and R&D Outlook

Teva’s focus on its branded pipeline and biosimilars indicates limited investment in expanding VYBRIQUE's indications or dosage forms. The drug's financial potential relies predominantly on existing markets and prescriber bases.

How Do Market and Financial Factors Interact?

The pharmaceutical market for Parkinson's treatment is resilient, but VYBRIQUE's financial outlook faces headwinds due to generics, price competition, and limited indication expansion. Its future revenue relies on maintaining market share among neurologists and endocrinologists and navigating regulatory pathways for new uses.

Key Takeaways

• VYBRIQUE operates in a mature Parkinson's market with steady growth driven by aging populations.
• Competition from other dopamine agonists limits market share.
• Limited brand-specific sales data hinder precise financial forecasting.
• Revenue growth prospects are constrained by generics and market saturation.
• Margins are at risk of erosion as formulations become generic.

FAQs

1. How does VYBRIQUE compare to other Parkinson’s medications in terms of effectiveness?
VYBRIQUE's efficacy aligns with other dopamine agonists but has a different side effect profile, which may influence prescriber choice depending on patient tolerance.

2. What are the major patent or exclusivity concerns for VYBRIQUE?
As a branded drug, VYBRIQUE's patent protections have expired or are nearing expiration, leading to increasing generic competition.

3. Are there any recent regulatory changes affecting VYBRIQUE?
No recent significant regulatory changes have been reported; the drug continues to hold approvals for its primary indications.

4. What is the outlook for off-label use of VYBRIQUE?
Off-label use for type 2 diabetes remains limited, and no substantial clinical evidence supports broader adoption.

5. Which regions represent growth opportunities for VYBRIQUE?
Growth opportunities exist mainly in the U.S. and Europe, where Parkinson’s diagnosis rates are high, but market penetration has plateaued.

---

Citations
[1] IQVIA, "Global Parkinson’s Disease Market Analysis," 2021.